AbbVie Entered into a Co-Development & License Agreement with Gedeon Richter to Develop & Commercialize Dopamine Receptor Modulators for Neuropsychiatric Diseases

Published: Mar 11, 2022 | Tags: AbbVie, Gedeon Richter, Dopamine Receptor Modulators, Neuropsychiatric Diseases

Passage Bio Reports the First Patient Dosing of PBKR03 in the P-I/II (GALax-C) Trial for the Treatment of Infantile Krabbe Disease

Published: Mar 11, 2022 | Tags: Passage Bio, P-I/II, GALax-C Trial, Infantile Krabbe Disease

Amarin Publishes Results of Vascepa (icosapent ethyl) in (REDUCE-IT) Study for the Treatment of Cardiovascular Diseases in JAHA 2022

Published: Mar 11, 2022 | Tags: Amarin, Vascepa, icosapent ethyl, REDUCE-IT Study, Cardiovascular Diseases, JAHA 2022

Erasca Entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate ERAS-007 and Erbitux (cetuximab) for Metastatic Colorectal Cancer

Published: Mar 11, 2022 | Tags: Erasca, Eli Lilly, ERAS-007, Cetuximab, Metastatic Colorectal Cancer

Samsung Bioepis and Biogen’s Byooviz (biosimilar, ranibizumab) Receive the Health Canada Approval for the Treatment of Retinal Vascular Disorders

Published: Mar 11, 2022 | Tags: Samsung Bioepis, Biogen, Byooviz, biosimilar, ranibizumab, Health Canada, Approval, Retinal Vascular Disorders

AbbVie Reports Results of Qulipta (atogepant) in P-III (PROGRESS) Trial for the Preventive Treatment of Chronic Migraine

Published: Mar 11, 2022 | Tags: AbbVie, Qulipta, atogepant, P-III, PROGRESS Trial, Chronic Migraine

Everest Licensing Partner Venatorx Report Results of Cefepime-Taniborbactam in P-III (CERTAIN-1) Study for Complicated Urinary Tract Infections

Published: Mar 10, 2022 | Tags: Everest, Venatorx, Cefepime-Taniborbactam, P-III, CERTAIN-1 Study, Complicated Urinary Tract Infections

Antengene’s ATG-101 Receives the NMPA’s IND Approval for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Published: Mar 10, 2022 | Tags: Antengene, ATG-101, NMPA, IND, Approval, Solid Tumors, Non-Hodgkin Lymphoma

Abivax Reports One-Year Maintenance Results of ABX464 in P-IIa Trial for the Treatment with Rheumatoid Arthritis

Published: Mar 10, 2022 | Tags: Abivax, ABX464, P-IIa, Trial, Rheumatoid Arthritis

Oncolytics Biotech Presents Results of Pelareorep + Bortezomib in P-Ib Study for the Treatment of Multiple Myeloma at the AACR 2022

Published: Mar 10, 2022 | Tags: Oncolytics Biotech, Pelareorep, Bortezomib, P-Ib, Study, Multiple Myeloma, AACR 2022

Denali Therapeutics Reports the Initiation of P-I/II Clinical Trial of DNL593 (PTV:PGRN) for the Treatment of Frontotemporal Dementia-Granulin

Published: Mar 10, 2022 | Tags: Denali Therapeutics, P-I/II, Clinical Trial, DNL593, PTV:PGRN, Frontotemporal Dementia-Granulin

Janssen Reports the Submission of a Type II Variation Application to the EMA for the Approval of a New Indication for Imbruvica (ibrutinib) for MCL

Published: Mar 10, 2022 | Tags: Janssen, Type II Variation Application, EMA, Imbruvica, ibrutinib, MCL

Pfizer Initiates P-II/III (EPIC-PEDS) Trial of Paxlovid (nirmatrelvir) for the treatment of Pediatric Patients with COVID-19

Published: Mar 09, 2022 | Tags: Pfizer, P-II/III, EPIC-PEDS Trial, Paxlovid, nirmatrelvir, COVID-19

Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A

Published: Mar 09, 2022 | Tags: Sobi, Sanofi, Efanesoctocog Alfa, BIVV001, P-III, XTEND-1 Study, Haemophilia A

Inventiva Reports the US FDA’s Acceptance of IND for Review of Lanifibranor and Empagliflozin for the Treatment of NASH and T2D

Published: Mar 09, 2022 | Tags: Inventiva, US, FDA, IND, Lanifibranor, Empagliflozin, NASH, T2D

Genmab’s Epcoritamab (DuoBody-CD3xCD20) Receives the US FDA’s Orphan-Drug Designation for the Treatment of Follicular Lymphoma

Published: Mar 09, 2022 | Tags: Genmab, Epcoritamab, DuoBody-CD3xCD20, US, FDA, Orphan-Drug Designation, Follicular Lymphoma

BridgeBio Entered into an Asset Purchase Agreement with Sentynl to Commercilize Nulibry (fosdenopterin) for Molybdenum Cofactor Deficiency

Published: Mar 09, 2022 | Tags: BridgeBio, Sentynl, Nulibry, fosdenopterin, Molybdenum Cofactor Deficiency

BioNTech Expands its 2020 Collaboration with Regeneron to Advance FixVac and Libtayo (cemiplimab) for the Treatment of NSCLC

Published: Mar 09, 2022 | Tags: BioNTech, 2020, Regeneron, FixVac, Libtayo, cemiplimab, NSCLC

Valneva Reports Completion of VLA1553 in P-III (VLA1553-301) Trial for the Treatment of Chikungunya

Published: Mar 08, 2022 | Tags: Valneva, VLA1553, P-III, VLA1553-301 Trial, Chikungunya

Voyager Therapeutics Entered into a License Option Agreement with Novartis to Develop Gene Therapies for the Treatment of Neurological Diseases

Published: Mar 08, 2022 | Tags: Voyager Therapeutics, Novartis, Gene Therapies, Neurological Diseases

Alpine Immune Sciences Reports the US FDA's Clinical Hold on (NEON-2) Trial of Davoceticept (ALPN-202) for Advanced Malignancies

Published: Mar 08, 2022 | Tags: Alpine Immune Sciences, US, FDA, Clinical Hold, NEON-2 Trial, Davoceticept, ALPN-202, Pembrolizumab, Advanced Malignancies

Targovax ASA Entered into a Clinical Collaboration and Supply Agreement with Agenus TG Mutant KRAS Cancer Adjuvanted with QS-21 STIMULON

Published: Mar 08, 2022 | Tags: Targovax ASA, Agenus, TG Mutant, KRAS Cancer, QS-21 STIMULON

Astellas Reports Results of Fezolinetant in P-III (SKYLIGHT 4) Trial for the Treatment of Vasomotor Symptoms Associated with Menopause

Published: Mar 08, 2022 | Tags: Astellas, Fezolinetant, P-III, SKYLIGHT 4 Trial, Vasomotor Symptoms, Menopause

Merck Reports Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-716) Trial for the Treatment of Resected Stage IIB and IIC Melanoma

Published: Mar 08, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-716 Trial, Stage IIB, IIC Melanoma

Spectrum Presents Results of Poziotinib in (ZENITH20) Clinical Trial as 1L Treatment of NSCLC at ESMO TAT 2022

Published: Mar 07, 2022 | Tags: Spectrum, Poziotinib, ZENITH20 Clinical Trial, NSCLC, ESMO TAT, 2022

Kintor Pharma Reports the Completion of Patient Enrollment in P-II Clinical Trial of KX-826 for Female Patients with Androgenetic Alopecia

Published: Mar 07, 2022 | Tags: Kintor Pharma, P-II, Clinical Trial, KX-826, Androgenetic Alopecia

Equillium Reports Initiation of P-III (EQUATOR) Study for Itolizumab as 1L Treatment of Acute Graft-Versus-Host Disease

Published: Mar 07, 2022 | Tags: Equillium, P-III, EQUATOR Study, Itolizumab, Acute Graft-Versus-Host Disease

BMS’s Opdivo (nivolumab) Receives the US FDA’s Approval as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

Published: Mar 07, 2022 | Tags: BMS, Opdivo, nivolumab, US, FDA, Approval, Non-Small Cell Lung Cancer

Junshi Biosciences and Coherus Publishes Results of Toripalimab in P-III (JUPITER-06) Study for Esophageal Squamous Cell Carcinoma in Cancer Cell

Published: Mar 07, 2022 | Tags: Junshi Biosciences, Coherus, Toripalimab, P-III, JUPITER-06 Study, Esophageal Squamous Cell Carcinoma, Cancer Cell

Altamira Entered into an Exclusive License and Distribution Agreement with Nuance Pharma to Develop and Commercialize Bentrio Nasal Spray

Published: Mar 07, 2022 | Tags: Altamira, Nuance Pharma, Bentrio Nasal Spray